srch

30.09.2021 · General and administrative expenses included $13.7 million in stock-based compensation expenses for the third quarter of 2021. Net Income (Loss): Net loss was $117.2 million for the third quarter of 2021, or a net loss per share of $2.00, as compared to a net income of $634.0 million for the third quarter of 2020, or a diluted net income per ...

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders.

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

07.12.2021 · Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The ...

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer ...

28.10.2021 · Blueprint Medicines Corp (NASDAQ:BPMC) Q3 2021 Earnings Call Oct 28, 2021, 8:30 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good ...

Get Blueprint Medicines Corp (BPMC:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

In 2014, he joined Blueprint Medicines as Chief Executive Officer and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline.

Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company is focused on ...

1 dag siden · BLUEPRINT MEDICINES CORP: Change in Directors or Principal Officers, Financial Statements.. AQ. 12/09: Blueprint Medicines Corporation Appoints Daniella Beckman to Its Board of Directors and.. CI. 12/07: Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR.

Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers ...

28.07.2021 · MD Anderson and Blueprint Medicines will jointly design translational studies, and Blueprint Medicines will provide funding, research compounds and additional support. As part of the agreement, MD Anderson is eligible to receive certain payments based on the future development of BLU-222.

Find the latest Blueprint Medicines Corporation (BPMC) stock quote, history, news and other vital information to help you with your stock trading and ...

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.

These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has …

19 rader · 01.12.2021 · Blueprint Medicines and Roche have co-exclusive rights to develop and …

28.12.2021 · Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy.

Company Description: Blueprint Medicines is a precision therapy company that identifies kinases that are drivers of genomically defined diseases and ...